# Telara Pharma SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/telara-pharma-sl

- Industry: Biotechnology
- Headquarters: Madrid, Spain
- Website: www.telarapharma.com
- Total disclosed funding: $0.1M
- Latest round: Seed (May 10, 2021)
- Investors on record: 1

## About

Based in Spain, Telara Pharma SL operates as a biopharmaceutical company focused on developing innovative therapies for severe inflammatory disorders, with a special emphasis on Acute Kidney Injury (AKI).Telara Pharma SL specializes in repurposing cilastatin to create therapies for severe inflammatory disorders, particularly Acute Kidney Injury (AKI). Founded in 2020 and headquartered in Madrid, Spain, the company raised EUR 100,000 in Seed funding led by Genesis Biomed on May 10, 2021. This funding supports their focus on advancing cilastatin's clinical application. The founder's background details are not available.Telara Pharma specializes in repurposing cilastatin, a drug initially used to address various kidney functions, into innovative therapies aimed at treating severe inflammatory disorders, particularly Acute Kidney Injury (AKI). The core product, cilastatin, functions as a competitive blocker of renal dehydropeptidase I (DHP-I), protecting renal tubular cells from damage caused by nephrotoxic agents, such as cisplatin, cyclosporine, and gentamicin, as well as conditions like sepsis. The company’s research has established cilastatin as a promising therapeutic alternative to currently unapproved drug therapies for AKI, which affects millions globally. Telara Pharma primarily targets healthcare professionals and institutions engaged in nephrology and critical care, focusing on markets in North America and Europe, where the need for effective AKI treatments is particularly acute.The revenue model of Telara Pharma is centered around partnerships and collaborations with healthcare entities, clinical trial sponsors, and potentially pharmaceutical companies looking to license cilastatin for further development. The company’s transactions typically occur through licensing agreements for their flagship product, cilastatin, which is in advanced clinical trial phases aimed at mitigating the impact of AKI caused by both toxic agents and sepsis. These agreements may involve milestone payments, royalties, or profit-sharing arrangements contingent upon successful trial outcomes and subsequent market entry. The company also anticipates revenue from future proprietary programs targeting neuroinflammatory disorders, further diversifying its income streams as they advance their clinical pipeline. The EBITDA for the most recent year, 2023, stands at EUR 59,176.50.Telara Pharma plans to continue developing cilastatin as a therapy for Acute Kidney Injury and is also exploring new proprietary programs aimed at treating neuroinflammatory disorders. The recent Seed funding of EUR 100,000 will be utilized to advance cilastatin through its clinical trial stages, helping to establish its efficacy and safety for future market entry. The company is focused on expanding into North American and European markets where there is a high demand for effective AKI treatments.

## Funding rounds

- Seed, May 10, 2021, $0.1M — Genesis Biomed

## Investors

- Genesis Biomed (https://capitalatlas.ai/funds/genesis-biomed) — Seed